Please ensure Javascript is enabled for purposes of website accessibility

Better Buy: Eli Lilly vs. Pfizer

By Prosper Junior Bakiny – Aug 28, 2020 at 7:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both of these pharma giants are working on a coronavirus vaccine, but there's more to the story.

Eli Lilly (LLY 1.17%) and Pfizer (PFE 0.59%) are two of several pharma giants in the race to combat COVID-19. Eli Lilly is currently evaluating three potential therapies for the disease in clinical trials, while Pfizer has kicked off a phase 3 study for its lead COVID-19 vaccine candidate. So far this year, Eli Lilly has outperformed Pfizer in the stock market.

While Eli Lilly is up by almost 13% year to date, Pfizer is down by over 3% during the same period. The S&P 500 has recovered its losses and gained 6.2% on the year. Both of these stocks have exciting growth prospects. But which one will outperform the other moving forward? Let's dig into their respective businesses and decide which is the better buy today. 

LLY Chart

LLY data by YCharts

The case for Eli Lilly

Eli Lilly's COVID-19 programs include two potential antibody treatments called LY-CoV555 and JS016, and Olumiant, which is already approved for the treatment of rheumatoid arthritis (RA).In collaboration with the National Institutes of Health, the company kicked off a phase 3 clinical trial for LY-CoV555 in long-term care facilities earlier this month to test its effectiveness in preventing infection from the SARS-CoV-2 virus that causes COVID-19. All of the trial's participants will be residents or employees in nursing homes.

The company also started a phase 1 clinical trial for JS016 on June 8. This study is evaluating the safety, tolerability, immunogenicity (the ability to trigger an immune response in the body), and pharmacokinetics (the way the body processes the treatment) of JS016 in healthy volunteers who haven't been diagnosed with COVID-19.

And the pharma giant is evaluating Olumiant as a treatment for hospitalized COVID-19 patients. By inhibiting the activity of certain enzymes, Olumiant is able to control inflammation in patients with RA. Through a similar mechanism, Eli Lilly thinks the drug could help reduce cytokine storms in those with severe cases of COVID-19. A cytokine storm occurs when the body releases too many cytokines (a type of protein) into the blood too quickly, leading to hyperinflammation. Eli Lilly also thinks that Olumiant could prevent host cells from making more copies of the SARS-CoV-2 virus.

Eli Lilly boasts exciting products beyond its coronavirus programs, with Trulicity as probably the most notable of the bunch. During the company's second quarter, which ended June 30, the diabetes drug generated $1.2 billion in sales, representing a 20% year-over-year increase. While Trulicity is by far the company's best-selling product, several of its other drugs are gaining momentum. Sales of Olumiant increased by 42% to $145 million during the second quarter, while cancer drug Verzenio's sales jumped by 56% to $208.6 million.

Man standing in front of two diverging paths.

Image source: Getty Images.

Back in mid-June, Eli Lilly's stock experienced its biggest one-day gains of the year when it announced positive results from a phase 3 study investigating Verzenio as a treatment for early-stage breast cancer. The company will soon seek regulatory approval for the drug for this purpose. Eli Lilly also has more than two dozen ongoing clinical trials, and the company should be able to enrich its lineup over time. Given its rich pipeline and several products with sales growing at a good clip, I expect Eli Lilly's stock to continue to reward investors.

The case for Pfizer 

Pfizer, meanwhile, is partnering with BioNTech (BNTX 2.08%) to develop a COVID-19 vaccine. The two companies recently kicked off a phase 3 clinical trial for their lead candidate, BNT162b2. This study will enroll up to 30,000 participants, with two primary endpoints: the prevention of COVID-19 in those who have not been infected by SARS-CoV-2, and the prevention of COVID-19 in those who have already contracted the virus.

This candidate is considered one of the leaders in the coronavirus vaccine race. Pfizer's goal is to have 100 million doses ready by year's end, pending regulatory approval. The company could benefit immensely from this market opportunity, but it has more than its coronavirus efforts going its way. Pfizer's biopharma business continues to perform well thanks to products such as anticoagulant Eliquis and cancer drug Ibrance. During its second quarter, which ended June 30, sales of Eliquis came in at $1.3 billion, a 17% year-over-year increase. Ibrance's revenue was also $1.3 billion, 7% higher than the prior-year quarter.

Pfizer is in the process of spinning off its slumping generics business, Upjohn, to Mylan (MYL), a transaction that should be complete by the end of the year. This will leave Pfizer able to focus on its more profitable biopharma business. With nearly two dozen ongoing phase 3 studies, the company is looking to add more products to its already strong starting lineup of drugs. Thanks to its COVID-19 program and strengthened biopharma business, Pfizer's stock should bounce back from its 2020 dip. 

Which is the better buy?

While Eli Lilly's performance on the market year to date is better than Pfizer's, the latter has performed better over the most recent months. Since March 23, Pfizer's shares have climbed by 36.5%, while Eli Lilly's stock is up by 25.6%. Also, Pfizer arguably fared better than Eli Lilly during the second quarter. 


Market Cap


Year-Over-Year Revenue Change

Net Income

Profit Margin


$216 billion

$11.8 billion


$3.4 billion


Eli Lilly

$143 billion

$5.5 billion


$1.4 billion


Sources: YCharts, Pfizer and Eli Lilly financial Statements.

Pfizer's revenue may have declined by 11% against a drop of only 2% for Eli Lilly, but sales from Pfizer's biopharma segment, which accounted for 83% of its revenue and will soon become its only operational segment, increased by 4%. Meanwhile, Pfizer posted a higher net income and a higher profit margin. Pfizer is currently trading at a trailing P/E of 15 and a forward P/E of 13.5, suggesting that the market has faith in its rebound.

This compares favorably with Eli Lilly's trailing P/E of 24.5 and its forward P/E of 20.1. With a higher revenue, higher net income, higher profit margin, and more attractive valuation, I think Pfizer is the better pharma buy today.

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$44.09 (0.59%) $0.26
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$311.10 (1.17%) $3.60
Viatris Inc. Stock Quote
Viatris Inc.
BioNTech SE Stock Quote
BioNTech SE
$130.30 (2.08%) $2.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.